SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following conditional marketing authorization for ANKTIVA in Europe, extending its market to 33 countries for hard-to-treat bladder cancer, while high-level discussions in the Middle East signal further global expansion and a broader BioShield Platform. The news has ignited significant community buzz around the company's global reach and humanitarian mission, intensifying expectations of a short squeeze amidst its transformation into a globally validated oncology player.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc (FJET) is trending as its IPO quiet period concludes, driving speculation about potential news such as an FAA Space Launch license. The community is actively discussing the stock's extremely low float and high insider ownership, fueling short squeeze narratives and optimistic price targets amidst broader sector excitement around the upcoming SpaceX IPO.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is a major talking point after reporting strong revenue but lowering its profit outlook, partly due to acquisition costs, igniting debate between investors seeing a long-term cybersecurity buying opportunity and those concerned about AI's impact on software valuations.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly anticipates its BLA resubmission for Deramiocel by month-end, following robust Phase 3 HOPE-3 data for Duchenne Muscular Dystrophy. Investors are closely watching for this regulatory milestone, alongside increasing institutional ownership and ongoing discussions around broader FDA consistency that could impact biotechs like CAPR.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after institutional investors, notably Cormorant Asset Management, significantly increased their position, fueling speculation of a short squeeze. The community is buzzing with excitement over the recent Fast Track designation, upcoming Investor Day, and persistent buyout chatter, believing the stock is undervalued.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending amidst strong community speculation over activist investor Nelson Peltz's comments on its undervaluation, driving discussions of a potential buyout or short squeeze following recent market movements.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after NVIDIA's 13F filing disclosed it no longer holds a stake, sparking debate among investors. While many view this as an overreaction to old news, emphasizing the company's strong fundamentals and institutional buying, others interpret NVIDIA's exit as a sign of diminished confidence in the data center provider's outlook.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as conversations buzz around promising "physical silicon results" for its Mears Silicon Technology (MST) in Gate-All-Around (GAA) nanosheets, hinting at significant power savings for AI chips, and its GaN-on-Si concept advancing to a proposal stage. This technical progress, coupled with unprecedented trading volume and management's renewed confidence with performance-linked bonuses, fuels a community debate between long-awaited commercial breakthroughs and concerns over the pre-revenue company's history of speculative hype.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending following its multi-year U.S. brewing and commercial partnership with the Carlsberg Group, stirring community debate on its non-cannabis growth strategy, while investors closely monitor anticipated updates on U.S. federal cannabis rescheduling to Schedule III and its potential, though debated, impact on the Canadian LP.

Fiverr International Ltd. develops an e-commerce platform that allows people to buy and sell digital services. It operates through the following geographical segments: U.S., Europe, Asia Pacific, Rest of the World and Israel. The firm offers digital marketing, graphics and design, video and animation, writing and translation, and music and audio. The company was founded by Micha Kaufman and Shai Wininger in 2009 and is headquartered in Tel Aviv, Israel.

Fiverr International Ltd

Fiverr is a trending topic following its Q4 earnings beat and organizational restructuring to become "AI-native," which accompanied cautious FY26 guidance and a new share repurchase authorization. Community discussions are heavily split between concerns about AI's disruptive potential to the gig economy and strong conviction that the stock is deeply undervalued and poised for a turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Moderate Buy" by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One...

Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit

Executives from Lexeo Therapeutics (NASDAQ:LXEO) outlined regulatory plans, clinical data, and manufacturing updates for its lead gene therapy programs during a presentation at Guggenheim's 2026...

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.2% - Time to Sell?

Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 3.2% - Should You Sell...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Moderate Buy" from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst...

Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Rises By 52.5%

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 10,830,747 shares, a...

Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Down - Here's What Happened

Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Down - What's Next...

Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9% - Still a Buy?

Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9% - Here's Why...

Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 5.5% - What's Next?

Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 5.5% - Here's What Happened...

Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 3.5% - Here's What Happened

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.5% - Time to Sell...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has earned an average rating of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

LXEO
Lexeo Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LXEO News

LXEOLexeo Therapeutics Inc.